600329.SS
600329.SS
CNE000001808
TIANJIN PHARMACEUTICAL DA REN T
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 4.917.335.979 7.306.736.059
32.7%
Cost of Revenue 1.277.410.418 3.786.015.011
66.3%
Gross Profit 3.639.925.561 3.520.721.047
3.4%
2.668.774.802 2.665.510.824
0.1%
Operating Income 971.150.759 855.210.224
13.6%
Pretax Income 2.487.451.831 2.578.782.876
3.5%
Net Income Common Stockholders 2.131.021.537 2.229.334.236
4.4%
-- --
--
-- --
--
ende